medigraphic.com
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

2019, Number 3

<< Back Next >>

Rev Invest Clin 2019; 71 (3)

Evaluation of the Royal Free Hospital Cirrhosis Glomerular Filtration Rate Formula in Hispanic Patients with Cirrhosis: An External Validation

Tejeda-Maldonado J, Niño-Cruz JA, Cruz-Rivera C, Torre A, Aguirre-Valadez J

Language: English
References: 46
Page: 195-203
PDF size: 280.78 Kb.


ABSTRACT

Background and Aims: Glomerular filtration rate (GFR) measurement in patients with liver cirrhosis (LC) is the ideal method for adequate evaluation of kidney function. However, it is invasive, costly, and not widely accessible. Moreover, GFR estimation in patients with cirrhosis has been inaccurate. The aim of the present study was to evaluate and validate the recently described Royal Free Hospital (RFH) formula in a Hispanic cohort of patients with LC and compare it with other formulas, including the CKD-EPI cystatin C equation. Methods: GFR was measured through the renal clearance of Tc-99m DTPA; it was cross-sectionally evaluated and compared with GFRs that were estimated utilizing the following formulas: RFH, Cockcroft-Gault, 6-variable Modification of Diet in Renal Disease-6, CKD-EPI cystatin C, CKD-EPI Creatinine, and CKD-EPI Cystatin C-Creatinine. Results: We included 76 patients (53% women). The mean measured GFR in the entire cohort was 64 ml/min/1.73m2; 54% of the patients had a GFR ‹ 60 ml/min/1.73 m2 at the time of evaluation. The RFH formula and the CKD-EPI cystatin C formula showed the best performance, with a p30 of 62% and 59%, respectively. All formulas performed poorly when GFR was ‹ 60 ml/min/1.73 m2. Conclusions: The RFH formula showed a better performance than the other formulas based on serum creatinine in a Hispanic population with LC. There was no difference in performance between the RFH formula and the CKD-EPI cystatin C formula.


REFERENCES

  1. Hecker R, Sherlock S. Electrolyte and circulatory changes in terminal liver failure. Lancet. 1956;271:1121-5.

  2. Wiesner R, Edwards E, Freeman R, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology. 2003;124:91-6.

  3. De Souza V, Hadj-Aissa A, Dolomanova O, et al. Creatinineversus cystatine C-based equations in assessing the renal function of candidates for liver transplantation with cirrhosis. Hepatology. 2014;59:1522-31.

  4. Torre A, Aguirre-Valadez JM, Arreola-Guerra JM, et al. Creatinine versus cystatin C for estimating GFR in patients with liver cirrhosis. Am J Kidney Dis. 2016;67:342-4.

  5. Mindikoglu AL, Dowling TC, Weir MR, et al. Performance of chronic kidney disease epidemiology collaboration creatininecystatin C equation for estimating kidney function in cirrhosis. Hepatology. 2014;59:1532-42.

  6. Mindikoglu AL, Dowling TC, Magder LS, et al. Estimation of glomerular filtration rate in patients with cirrhosis by using new and conventional filtration markers and dimethylarginines. Clin Gastroenterol Hepatol. 2016;14:624-3200.

  7. Cholongitas E, Ioannidou M, Goulis I, et al. Comparison of creatinine and cystatin formulae with 51 chromium-ethylenediaminetetraacetic acid glomerular filtration rate in patients with decompensated cirrhosis. J Gastroenterol Hepatol. 2017; 32:191-8.

  8. Kalafateli M, Wickham F, Burniston M, et al. Development and validation of a mathematical equation to estimate glomerular filtration rate in cirrhosis: the royal free hospital cirrhosis glomerular filtration rate. Hepatology. 2017;65:582-91.

  9. Pedersen JS, Kimer N, Henriksen JH, Bendtsen F, Møller S. The royal free hospital cirrhosis glomerular filtration rate: validation in a danish cohort. Hepatology. 2017;66:1360-1.

  10. Myers GL, Miller WG, Coresh J, et al. Recommendations for improving serum creatinine measurement: a report from the laboratory working group of the national kidney disease education program. Clin Chem. 2006;52:5-18.

  11. Grubb A, Blirup-Jensen S, Lindström V, et al. First certified reference material for cystatin C in human serum ERM-DA471/IFCC. Clin Chem Lab Med. 2010;48:1619-21.

  12. Inker LA, Schmid CH, Tighiouart H. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med. 2012;367:20-9.

  13. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39:S1-266.

  14. Nair S, Verma S, Thuluvath PJ. Pretransplant renal function predicts survival in patients undergoing orthotopic liver transplantation. Hepatology. 2002;35:1179-85.

  15. Francoz C, Glotz D, Moreau R, Durand F. The evaluation of renal function and disease in patients with cirrhosis. J Hepatol. 2010; 52:605-13.

  16. Caregaro L, Menon F, Angeli P, et al. Limitations of serum creatinine level and creatinine clearance as filtration markers in cirrhosis. Arch Intern Med. 1994;154:201-5.

  17. Haddadin Z, Lee V, Conlin C, et al. Comparison of performance of improved serum estimators of glomerular filtration rate (GFR) to 99m Tc-DTPA GFR methods in patients with hepatic cirrhosis. J Nucl Med Technol. 2017;45:42-9.

  18. Fleming JS, Zivanovic MA, Blake GM, et al. Guidelines for the measurement of glomerular filtration rate using plasma sampling. Nucl Med Commun. 2004;25:759-69.

  19. Wickham F, Burniston MT, Xirouchakis E, et al. Development of a modified sampling and calculation method for isotope plasma clearance assessment of the glomerular filtration rate in patients with cirrhosis and ascites. Nucl Med Commun. 2013; 34:1124-32.

  20. Wickham F, Burniston MT, McMeekin H, Hilson AJ, Burroughs AK. Validation and impact of a new technique for assessment of glomerular filtration rate in patients with liver disease. Nucl Med Commun. 2015;36:168-79.

  21. Krones E, Fickert P, Zitta S, et al. The chronic kidney disease epidemiology collaboration equation combining creatinine and cystatin C accurately assesses renal function in patients with cirrhosis. BMC Nephrol. 2015;16:196.

  22. Rennard S, Thomashow B, Crapo J, et al. Introducing the COPD foundation guide for diagnosis and management of COPD, recommendations of the COPD foundation. COPD. 2013;10: 378-89.

  23. Duckers JM, Evans BA, Fraser WD, et al. Low bone mineral density in men with chronic obstructive pulmonary disease. Respir Res. 2011;12:101.

  24. Ryan CS, Petkov VI, Adler RA. Osteoporosis in men: the value of laboratory testing. Osteoporos Int. 2011;22:1845-53.

  25. Yamauchi Y, Yasunaga H, Sakamoto Y, et al. Mortality associated with bone fractures in COPD patients. Int J Chron Obstruct Pulmon Dis. 2016;11:2335-40.

  26. Watanabe R, Tanaka T, Aita K, et al. Osteoporosis is highly prevalent in Japanese males with chronic obstructive pulmonary disease and is associated with deteriorated pulmonary function. J Bone Mineral Metab. 2015;33:392-400.

  27. Moon JY, Kim KJ, Moon MH, Chung BC, Choi MH. A novel GC-MS method in urinary estrogen analysis from postmenopausal women with osteoporosis. J Lipid Res. 2011;52:1595-603.

  28. Ford ES, Croft JB, Mannino DM, et al. COPD surveillance – United states, 1999-2011. Chest. 2013;144:284-305.

  29. Sakurai-Iesato Y, Kawata N, Tada Y, et al. The relationship of bone mineral density in men with chronic obstructive pulmonary disease classified according to the global initiative for chronic obstructive lung disease (GOLD) combined chronic obstructive pulmonary disease (COPD) assessment system. Intern Med. 2017;56:1781-90.

  30. Celli BR, MacNee W, ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004;23:932-46.

  31. Ferguson GT, Calverley PM, Anderson JA, et al. Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a revolution in COPD health study. Chest. 2009; 136:1456-65.

  32. Jung HJ, Park HY, Kim JS, Yoon JO, Jeon IH. Bone mineral density and prevalence of osteoporosis in postmenopausal Korean women with low-energy distal radius fractures. J Korean Med Sci. 2016;31:972-5.

  33. Graat-Verboom L, Wouters EF, Smeenk FW, et al. Current status of research on osteoporosis in COPD: a systematic review. Eur Respir J. 2009;34:209-18.

  34. Inoue D, Watanabe R, Okazaki R. COPD and osteoporosis: links, risks, and treatment challenges. Int J Chron Obstruct Pulmon Dis. 2016;11:637-48.

  35. Choi JW, Pai SH. Association between respiratory function and osteoporosis in pre- and postmenopausal women. Maturitas. 2004;48:253-8.

  36. Lee IS, Leem AY, Lee SH, et al. Relationship between pulmonary function and bone mineral density in the Korean national health and nutrition examination survey. Korean J Intern Med. 2016; 31:899-909.

  37. Okazaki R, Watanabe R, Inoue D. Osteoporosis associated with chronic obstructive pulmonary disease. J Bone Metab. 2016; 23:111-20.

  38. Liang B, Feng Y. The association of low bone mineral density with systemic inflammation in clinically stable COPD. Endocrine. 2012;42:190-5.

  39. Liu WT, Kuo HP, Liao TH, et al. Low bone mineral density in COPD patients with osteoporosis is related to low daily physical activity and high COPD assessment test scores. Int J Chron Obstruct Pulmon Dis. 2015;10:1737-44.

  40. Abbasi M, Zohal M, Atapour B, Yazdi Z. Prevalence of osteoporosis and its risk factors in men with COPD in qazvin. Int J Chronic Dis. 2016;2016:4038530.

  41. Vrieze A, de Greef MH, Wijkstra PJ, Wempe JB. Low bone mineral density in COPD patients related to worse lung function, low weight and decreased fat-free mass. Osteoporos Int. 2007; 18:1197-202.

  42. Vestbo J, Prescott E, Almdal T, et al. Body mass, fat-free body mass, and prognosis in patients with chronic obstructive pulmonary disease from a random population sample: findings from the copenhagen city heart study. Am J Respir Crit Care Med. 2006;173:79-83.

  43. Bai P, Sun Y, Jin J, et al. Disturbance of the OPG/RANK/RANKL pathway and systemic inflammation in COPD patients with emphysema and osteoporosis. Respir Res. 2011;12:157.

  44. Sarwar G, Bisquera A, Peel R, et al. The effect of inhaled corticosteroids on bone mineral density measured by quantitative ultrasonography in an older population. Clin Respir J. 2018; 12:659-65.

  45. Mathioudakis AG, Amanetopoulou SG, Gialmanidis IP, et al. Impact of long-term treatment with low-dose inhaled corticosteroids on the bone mineral density of chronic obstructive pulmonary disease patients: aggravating or beneficial? Respirology. 2013;18:147-53.

  46. Hubbard R, Tattersfield A. Inhaled corticosteroids, bone mineral density and fracture in older people. Drugs Aging. 2004;21:631-8.




2020     |     www.medigraphic.com